Hua Xie

机构：Shanghai Institute of Materia Medica, Zhujiang Hospital, Zhongshan Hospital · ORCID：0000-0002-0207-4500

发表论文 290 篇 · 总被引 5299 次 · h-index 38

代表论文

• AM-DMF-SCP: Integrated Single-Cell Proteomics Analysis on an Active Matrix Digital Microfluidic Chip (2024 · JACS Au · 被引 60)
• Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations (2022 · Journal of Medicinal Chemistry · 被引 59)
• LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo (2021 · Cancer Science · 被引 51)
• From bench to bedside: current development and emerging trend of KRAS-targeted therapy (2023 · Acta Pharmacologica Sinica · 被引 39)
• Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants (2022 · ACS Medicinal Chemistry Letters · 被引 29)
• Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer (2024 · Journal of Medicinal Chemistry · 被引 22)